Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Research on the Evolution, Geometry, and Alterations of the Periorbital Region Based on Age and Deformations

NCT07080320 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2025-09-20
Last updated
2026-02-05

Condition(s) studied

Facial SkinMotion CaptureAgingPeriorbital RegionSkin MovementVertical Jump

Investigational drug(s) / intervention(s)

MoCap

MoCap: For each subject, the displacement of markers, the deformation of regions between markers, and the evolution of angles formed by the markers during facial expressions and vertical movements will be analyzed with MoCap. These will be compared between the two age groups (18-33 years vs. 50-65 years) using a MANOVA model. The reference values for marker displacement will be defined by the interval between the 2.5% and 97.5% percentiles of the values for each marker. If the distribution is Gaussian, the percentiles will be derived from the standard normal distribution; otherwise, the non-parametric method will be used. The intervention will be Interventions : * Recruitment of healthy and pathological subjects. * Full-face and macro images of the periorbital region * Measurement of periorbital skin properties using MoCap and standard reference tools. * Application of a tightening product (aloe vera) and periorbital massage. * Measurement of skin response to a vertical jump.

Study summary

The periorbital region of the face is a critical area affected by aging. Motion Capture (MoCap) allows the precise measurement of the mechanical properties of skin in this region. This study will validate MoCap as a tool for quantifying these properties, comparing it to traditional reference tools, and exploring how these properties evolve with age and external treatments. It will also assess MoCap's ability to detect the effects of various treatments such as tightening products and massages. Ultimately, this research will provide a deeper understanding of skin dynamics in the periorbital region and offer insights into both medical and cosmetic applications.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Female participants * Caucasian, Fitzpatrick skin types I-III * BMI between 18.5 and 27, healthy participants * Aged 18 to 65 years (inclusive) * Not under guardianship or curatorship * Informed written consent * Social security affiliation * Non-smokers for at least 5 years * No excessive UV exposure (artificial or natural) in the last 3 weeks prior to the study or during the study Exclusion Criteria: * Severe skin disorders preventing the application of electrodes or photo-reflective markers * Neurovascular history affecting the face * Ongoing treatments influencing facial tissues (e.g., corticosteroids) * Current sleep disorders * Psychiatric conditions or social interaction impairments * Inner ear or balance disorders * Osteoporosis, recent fractures, or fragile bone conditions * Pregnant or breastfeeding women * Under guardianship, curatorship, or legal protection

Primary outcome measure(s)

  • maximum displacement (in millimeters) of each marker placed on the face — day 1
    maximum displacement (in millimeters) of each marker placed on the face during standardized movements of the periorbital region

Trial sites (1)

FacilityCityRegionStatus
CHRU Amiens Amiens France
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07080320 on ClinicalTrials.gov ↗ ← All trials in France